If you thought cell therapy had suffered too many setbacks in recent years and was stuck in neutral – think again. In a recent Percepta poll of 250 randomly selected life science researchers working in biotechnology and pharmaceutical companies more than 20% are involved in projects focused on allogeneic or autologous cell therapy and/or regenerative medicine. Even more surprising…